Skip to main content

Advertisement

Table 1 Characteristics of included RCTs

From: Methodological reporting of randomized controlled trials in major hepato-gastroenterology journals in 2008 and 1998: a comparative study

Administrative indicators Trials in 2008 Trials in 1998 RR [95%CI] p value
  No. (%) No. (%)   
Top five kinds of disease
chronic hepatitis C 19(18%) 15(15%) 1.21 [0.58, 2.53] P = 0.62
inflammatory bowel disease 17(16%) 11(11%) 1.51 [0.67, 3.41] P = 0.32
liver cirrhosis 11(10%) 12(12%) - -
chronic hepatitis B 12(11%) - - -
colorectal cancer 8(7%) - - -
peptic ulcer - 15(15%) - -
liver cancer - 5(5%) - -
Region     
North America 36(34%) 30(30%) 1.17 [0.65, 2.10] P = 0.61
Europe 42(39%) 56(57%) 0.50 [0.28, 0.86] P = 0.01
Asia 19(18%) 8(8%) 2.46 [1.02, 5.90] P = 0.04
Australia 10(9%) 4(4%) 2.45 [0.74, 8.08] P = 0.14
Center     
Single-center 31(29%) 51(52%) 0.38 [0.22, 0.68] P = 0.001
Multi-center 76(71%) 48(48%) 2.60 [1.47, 4.63] P = 0.001
Funding source     
Industry 43(40%) 25(25%) 1.99 [1.10, 3.61] P = 0.02
Public 40(38%) 32 (32%) 1.25 [0.70, 2.22] P = 0.45
Public and industry 13(12%) 8(8%) 1.57 [0.62, 3.97] P = 0.34
Not specified 5(5%) 33(33%) 0.10 [0.04, 0.26] P < 0.001
None 6(5%) 1(1%) 5.82 [0.69, 49.24] P = 0.11
Ethics committee approval 105(98%) 86(87%) 7.94 [1.74, 36.13] P = 0.007
Informed consent from patients 100(93%) 81(82%) 3.17 [1.26, 7.97] P = 0.01